Phytohealth Corp (4108) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Phytohealth Corp TWD 3.95, price TWD 11.55, upside -65.8%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments.
Show more
PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. The Medical Diagnosis segment develops and sells smart medical imaging diagnostic products. The Precision Medical Equipment and Instruments segment engages in the research and development, manufacturing, and sale of ultrasound probes and analysis systems. Its products under development include PHN031, which has completed Phase II clinical trials for the treatment of osteoporosis, and PHN033, which has completed Phase II clinical trials for the treatment of diabetic nephropathy. The company is also developing PHN016, which is in Phase II clinical trials for the treatment of cancer, and PHN017, which is in Phase I trials for the treatment of severe infection-induced cytokine storm. In addition, it offers PG2 Lyophilized Injection for the treatment of cancer-related fatigue and capsules for acute moderate to severe pain. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.
Stock analysis
Phytohealth Corp (4108) currently trades at 11.55 TWD, while our model-based Fair Value estimate is 3.95 TWD, 65.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 81/100, which puts the evidence level at low.
Scenario range: 2.60 TWD (bear) to 4.93 TWD (bull), the price of 11.55 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Phytohealth Corp reported revenue of 135M TWD in FY2025 versus 169M TWD in FY2021, a compound −5.5%/yr. Reported net income was −58.2M TWD in FY2025.
Key figures
Market cap 2.2B TWD (≈ $69.2M) · P/S ratio 15.7 · EPS (TTM) −0.2200 TWD · Net margin −43.2% · Return on equity −4.0% · Return on assets (EBIT) −5.6% · Operating margin −108% · Revenue (TTM) 143M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −66%, 4108 screens richer than that median.
Fair Value models
Bear 2.60 TWDFair Value 3.95 TWDBull 4.93 TWD
Price 11.55 TWD · Upside -65.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: +20.4% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−126.3% (2020) → −129.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 586 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−65.8% · Bottom 25%
Profitability
Return on assets−4.3% · Bottom 25%
Net margin (TTM)−30.2% · Bottom 25%
Operating margin (TTM)−108.4% · Bottom 25%
Growth and dividend
Revenue growth15.7% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.48× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)79· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Phytohealth Corp Fair Value". https://www.fairvalue-calculator.com/stock/4108
Frequently asked questions
Is Phytohealth Corp (4108) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 3.95 TWD versus a price of 11.55 TWD, about −66% upside (overvalued).
What is the fair value of 4108?
Our model-based fair value for Phytohealth Corp is 3.95 TWD (as of Oct 2, 2026), built from audited fundamentals. The current price: 11.55 TWD.
What is the quality score of 4108?
Phytohealth Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phytohealth Corp (4108)?
Our model-based price target is the fair value of 3.95 TWD (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 2.60 TWD, optimistic scenario 4.93 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Phytohealth Corp stock forecast for 2026?
Our models put fair value at 3.95 TWD, about −66% upside versus a price of 11.55 TWD (overvalued). Cautious scenario 2.60 TWD, optimistic scenario 4.93 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Phytohealth Corp (4108)?
Phytohealth Corp reported trailing-twelve-month revenue of about 143M TWD (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Phytohealth Corp (4108)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phytohealth Corp it is 3.95 TWD per share (as of Oct 2, 2026), against a price of 11.55 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Phytohealth Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 4108 trades above its calculated fair value: price 11.55 TWD, fair value 3.95 TWD, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4108?
No. The price is what the market pays today (11.55 TWD); the fair value is what the company's own numbers justify (3.95 TWD). For Phytohealth Corp the two are 7.60 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Phytohealth Corp worth?
The market values Phytohealth Corp at about 2.2B TWD (market capitalisation, as of Oct 2, 2026). Per share that is 11.55 TWD; our models calculate a fair value of 3.95 TWD per share.
What do the bullish and bearish scenarios say about 4108?
Our models span a range for Phytohealth Corp: cautious scenario 2.60 TWD, base 3.95 TWD, optimistic 4.93 TWD per share (as of Oct 2, 2026, price 11.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Phytohealth Corp (4108)?
Balance-sheet figures for Phytohealth Corp (as of Oct 2, 2026): return on equity −4.0%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 4108 from its 52-week high?
Phytohealth Corp trades at 11.55 TWD, about 24% below its 52-week high of 15.25 TWD and 7% above the low of 10.75 TWD (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of 3.95 TWD is for.
Which stocks are comparable to Phytohealth Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phytohealth Corp stock attractive at the current price?
The data as of Oct 2, 2026: price 11.55 TWD, calculated fair value 3.95 TWD (−66%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4108 calculated?
We run Phytohealth Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.95 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Phytohealth Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phytohealth Corp (4108)?
The closing price on Oct 8, 2026 was 11.55 TWD. Our model-based fair value is 3.95 TWD, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phytohealth Corp right now?
The price sits above even our optimistic bull case (4.93 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (2.60 TWD to 4.93 TWD) leaves room in how you read the outcome.
Key figures of Phytohealth Corp
How large is the market capitalisation of Phytohealth Corp (4108)?
The market capitalisation of Phytohealth Corp is 2.2B TWD (≈ $69.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Phytohealth Corp (4108)?
The price-to-sales ratio of Phytohealth Corp is 15.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Phytohealth Corp (4108)?
Earnings per share at Phytohealth Corp are −0.2200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Phytohealth Corp (4108)?
The net margin of Phytohealth Corp is −43.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Phytohealth Corp (4108)?
The return on equity (ROE) of Phytohealth Corp is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phytohealth Corp (4108)?
On an EBIT basis the return on assets of Phytohealth Corp is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phytohealth Corp (4108)?
The operating margin of Phytohealth Corp is −108% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phytohealth Corp (4108)?
Revenue at Phytohealth Corp is growing +15.7% versus a year earlier (3y avg −0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Phytohealth Corp (4108)?
Earnings per share at Phytohealth Corp are growing +50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Phytohealth Corp (4108) generate?
The free cash flow of Phytohealth Corp is −45.3M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Phytohealth Corp (4108) hold?
Phytohealth Corp holds more cash than debt, 71.1M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Phytohealth Corp in the live analysis
One click puts Phytohealth Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
